Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (161-170 of 302) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2004
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trialPierre Fargeot, Jacques Bonneterre, Henri Roché, et al.
Digital Health|February 27, 2025
Structuring and centralizing breast cancer real-world biomarker data from pathology reports through C-LAB<sup>®</sup> artificial intelligence platformFlorent Le Borgne, Camille Garnier, Camille Morisseau, et al.
Breast Cancer Research : BCR|January 2, 2020
A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancerIain R Macpherson, Pavlina Spiliopoulou, Saeed Rafii, et al.
Cancers|July 24, 2021
Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients-First Results from the PAPESCO-19 Cohort StudyKe Zhou, Audrey Blanc-Lapierre, Valérie Seegers, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.
Future Oncology (London, England)|July 29, 2024
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancerErika P Hamilton, Cynthia Ma, Michelino De Laurentiis, et al.
Cancer Research|September 28, 2013
CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancerMarine Malleter, Sébastien Tauzin, Alban Bessede, et al.
The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.
The Lancet. Oncology|March 2, 2012
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 studyJean-Yves Pierga, Thierry Petit, Thierry Delozier, et al.
Pageof 31

Showing results (161-170 of 302) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2004
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trialPierre Fargeot, Jacques Bonneterre, Henri Roché, et al.
Digital Health|February 27, 2025
Structuring and centralizing breast cancer real-world biomarker data from pathology reports through C-LAB<sup>®</sup> artificial intelligence platformFlorent Le Borgne, Camille Garnier, Camille Morisseau, et al.
Breast Cancer Research : BCR|January 2, 2020
A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancerIain R Macpherson, Pavlina Spiliopoulou, Saeed Rafii, et al.
Cancers|July 24, 2021
Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients-First Results from the PAPESCO-19 Cohort StudyKe Zhou, Audrey Blanc-Lapierre, Valérie Seegers, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.
Future Oncology (London, England)|July 29, 2024
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancerErika P Hamilton, Cynthia Ma, Michelino De Laurentiis, et al.
Cancer Research|September 28, 2013
CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancerMarine Malleter, Sébastien Tauzin, Alban Bessede, et al.
The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.
The Lancet. Oncology|March 2, 2012
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 studyJean-Yves Pierga, Thierry Petit, Thierry Delozier, et al.
Pageof 31